Table 3.
Characteristics Of The Optimized Formulations
| Formulation | Size (d.nm) | PDI | Zeta Potential (mV) | DL (%) | EE (%) | BE (%) |
|---|---|---|---|---|---|---|
| DPNs | 146.0 ± 1.3 | 0.093 ± 0.036 | −3.61 ± 0.90 | 10.87 ± 0.96 | 65.21 ± 5.81 | – |
| DPPNs | 175.0 ± 2.8 | 0.121 ± 0.033 | 28.20 ± 2.03 | 11.14 ± 0.62 | 66.88 ± 3.62 | – |
| eBev-DPPNs | 217.7 ± 5.3 | 0.279 ± 0.049 | 0.85 ± 0.37 | 9.50 ± 0.30 | 56.97 ± 1.93 | 85.64 ± 0.28 |
| cBev-DPNs | 201.3 ±7.2 | 0.318 ± 0.084 | 0.31 ± 1.15 | 9.34 ± 0.07 | 56.01 ± 0.33 | 81.75 ± 2.12 |
Note: Data are expressed as mean ± SD, n = 3.
Abbreviations: DPNs, dexamethasone-loading PLGA nanoparticles; DPPNs, dexamethasone-loading PLGA/PEI nanoparticles; eBev-DPPNs, electrostatically-conjugated bevacizumab-bearing DPPNs; cBev-DPNs, chemically-conjugated bevacizumab-bearing DPNs; PDI, polydispersity index; PDI, polydispersity index; DL, drug loading; EE, encapsulation efficiency; BE, binding efficiency.